Molecules · 2024 · 13 citations · 45 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryNanomaterialsNanoparticle Drug DeliveryDrug EncapsulationNanomaterials For Drug DeliveryNanomedicineNanoparticle CharacterizationNanoparticle FormulationsOral NanocarriersDrug Delivery NanocarriersEncapsulationEncapsulation EfficiencyNanocarrier Encapsulation EfficiencyNanoparticle DeliveryNanoparticle Drug Delivery SystemsOral Drug Delivery FormulationsOral Drug Delivery Nanoparticles
The oral delivery strategy of natural anti-oxidant and anti-inflammatory agents has attracted great attention to improve the effectiveness of ulcerative colitis (UC) treatment. Herein, we developed a novel orally deliverable nanoparticle, carboxymethyl chitosan (CMC)-modified astaxanthin (AXT)-loaded nanoparticles (CMC-AXT-NPs), for UC treatment. The CMC-AXT-NPs were evaluated by appearance, morphology, particle size, ζ-potential, and encapsulation efficiency (EE). The results showed that CMC-AXT-NPs were nearly spherical in shape with a particle size of 34.5 nm and ζ-potential of -30.8 mV, and the EE of CMC-AXT-NPs was as high as 95.03%. The CMC-AXT-NPs exhibited preferable storage stability over time and well-controlled drug-release properties in simulated intestinal fluid. Additionally, in vitro studies revealed that CMC-AXT-NPs remarkably inhibited cytotoxicity induced by LPS and demonstrated superior antioxidant and anti-inflammatory abilities in Raw264.7 cells. Furthermore, CMC-AXT-NPs effectively alleviated clinical symptoms of colitis induced by dextran sulfate sodium salt (DSS), including maintaining body weight, inhibiting colon shortening, and reducing fecal bleeding. Importantly, CMC-AXT-NPs suppressed the expression of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β and ameliorated DSS-induced oxidative damage. Our results demonstrated the potential of CMC-modified nanoparticles as an oral delivery system and suggested these novel AXT nanoparticles could be a promising strategy for UC treatment.
45
REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis
Shuai Wang, Yanke Lin, Xue Yuan et al. · Nature Communications · 2018 · 355 citations · Full text